Bioinformatics and HIV Latency

Angela Ciuffi · Pejman Mohammadi · Monica Golumbeanu · Julia di Iulio · Amalio Telenti

Published online: 14 January 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Despite effective treatment, HIV is not completely eliminated from the infected organism because of the existence of viral reservoirs. A major reservoir consists of infected resting CD4 + T cells, mostly of memory type, that persist over time due to the stable proviral insertion and a long cellular lifespan. Resting cells do not produce viral particles and are protected from viral-induced cytopathicity or immune killing. However, these latently infected cells can be reactivated by stochastic events or by external stimuli. The present review focuses on novel genome-wide technologies applied to the study of integration, transcriptome, and proteome characteristics and their recent contribution to the understanding of HIV latency.

Keywords HIV · Latency · Bioinformatics · Integration · Transcription · Transcriptome · Proteome

Introduction

The study of biological processes, including viral infections, benefits from novel technologies for exploration and discovery. In the past decade, new developments have focused on genome-wide analyses, including high-throughput sequencing technologies for genome and transcriptome analyses, as well as mass spectrometry-based technologies for proteomic studies. These technologies aim at providing the most comprehensive snapshot picture of a specific cellular content, thereby generating large amounts of data. In turn, large-scale datasets require the development of tools and methods to handle and analyze these data adequately. This review focuses on experimental and bioinformatic methodologies applied to the topic of HIV latency.

HIV Latency

HIV infection is considered today a chronic disease, thanks to the efficacy of antiretroviral therapy (ART) [1, 2, 3–7]. ART aims at blocking multiple viral replication steps and enzymatic activities, i.e., entry, reverse transcriptase, integrase, and protease, thereby limiting virus escape through selection of variants. ART results in undetectable viremia in the plasma of HIV+ individuals but fails to achieve complete virus eradication, hence requiring life-long treatment [1, 2, 3–7]. HIV persistence is explained by the existence of reservoirs that are established early upon HIV exposure [8, 9–11]. Two types of reservoirs have been described that are not mutually exclusive and that are likely to co-exist in some individuals. The first reservoir consists in anatomical sanctuaries, such as the central nervous system, gut, or lungs, where ART drug concentration may be suboptimal due to incomplete penetration [12–14]. Infection may persist in these sites due to either partial inhibition of viral replication or to cell-to-cell spread of...
the virus [12, 13, 15]. The second reservoir relies on the persistence of HIV in long-lived cells in a latent and thus “hidden” state. This relies on HIV’s ability to stably insert its genome in the host cell chromosome, thereby ensuring its life-long association with the infected host cell. This latent cell reservoir consists mostly of resting memory CD4+ T cells, but other cells have been shown to contribute as well, including naïve CD4+ T cells, macrophages, dendritic cells, and hematopoietic progenitor cells [16–22]. Latently infected CD4+ T cells can be induced, i.e., reactivated, and are thus able to produce particles through stochastic transcription or through immune activation, thereby leading to intermittent detectable viremia or viremia rebound after ART cessation [2•, 3, 23••].

The reservoir of latently infected CD4+ T cells is currently considered to be the major obstacle to HIV cure. Global scientific efforts have focused on infected CD4+ T cells in order to understand the nature of latency, i.e., nature of post-integration blocks hampering viral particle production, as well as designing new strategies to stimulate cells to exit latency. For this purpose, multiple models have been developed to characterize various mechanisms that can contribute to HIV latency [24, 25]. Models have also been useful to test reactivation compounds inducing viral particle production from the latently infected CD4+ T cells [26••, 27–29]. The present review focuses on recent genome-wide analyses performed on the models of HIV latency (Table 1).

### The Inducible Reservoir

Available methods overestimate or underestimate the size of the latent viral reservoir. This is mainly due to (i) the use of blood samples as the source of the latent reservoir, (ii) the major presence of cells carrying defective viral genomes which obscures the proportion of latently infected cells, and (iii) the incomplete success of current methods used to reactivate latently infected cells in vitro. Indeed, it has been estimated that out of one million blood-purified resting CD4+ T cells from ART-treated individuals, on average, ~1000 cells (ranging approximately between 100 and 2000 cells) were infected by HIV and thus contained proviral DNA [30••]. However, only a small proportion of these HIV+ cells (11.7 %) carry replication-competent viral genome sequences and are thus inducible [31••]. Using phytohemagglutinin, interleukin-2, and irradiated peripheral blood mononuclear cells to stimulate CD4+ T cells in a viral outgrowth assay, only 1 % of HIV+ cells were successfully induced, thereby illustrating that current reactivation protocols and methods stimulate only a fraction of the total inducible reservoir [30••, 31••]. Other methods of stimulation using anti-CD3/CD28 and interleukin-7 for 7 days were able to induce particle production from 1.5 % of HIV+ cells (ranging from 0.6 to 2.4 % in the 13 patients tested) [23••]. Finally, reactivation of latently infected cells may occur stochastically and spontaneously at a frequency of 0.041 % (0.03–0.15 %) [23••].

These studies indicate that the latency is complex as stimulation does not lead to 100 % reactivation of latently infected cells [26••, 31••]. Cillo et al. also show that, under their stimulation conditions, 7.5 % of infected cells were expressing cell-associated RNA, an almost 40× increase in HIV transcription compared to unstimulated resting CD4+ T cells. The gap between the successful viral particle production and viral transcription suggests that transcriptional latency cannot recapitulate all aspects of the viral reservoir and that other post-integration blocks exist, consistent with multiple recent studies using latency-reactivating agents and multiple models of HIV latency [23••, 26••, 32••].

### Integration Site Location and HIV Latency

Reverse transcription of the viral RNA genome and its integration in the host cell chromosome are two hallmarks of retroviruses. In the past decade, thanks to the availability of the human genome sequence, many efforts have been focused on the understanding of the preferential site of HIV integration, as well as its consequences on the host cell, mostly regarding insertional mutagenesis [33–35]. HIV has been shown to integrate preferentially into active transcription units, with no preference for exons or introns, neither for orientation [34, 36, 37]. The site of integration may have consequences for both HIV transcription and host gene transcription because of chromatin arrangement and RNA interference [35, 38]. Therefore, the site of integration can affect the balance between viral transcriptional success and latency, as well as establish a balance between cell death and clonal expansion.

Analysis of integration site distribution commonly uses a three-step experimental approach: (i) DNA fragmentation (sonication, restriction enzymes), (ii) linker ligation, and (iii) PCR amplifications using primer annealing in the long terminal repeat (LTR) and primer annealing in the ligated linker [39–41]. The amplicons are sequenced using next-generation sequencing technologies, generating millions of short reads (ranging usually from ~20 bp to a few hundreds of bp). Virus sequences are removed and trimmed sequences are aligned to the human genome to locate the integration site. This method allows the efficient capture of the preferential pattern of integration site distribution according to the human reference genome annotations. However, it fails to quantify the frequency of integration sites occurring at the exact same location due to the bias caused by the PCR amplification step [42••]. This limitation was recently addressed using random shearing of the DNA or through the usage of random decamer primers tailed with a U5 sequence that allowed discriminating between two identical integration site locations originating from an
| HIV latency models                        | Analysis type | Experimental approach                                                                 | Computational tools/approaches                                      | Reference          |
|------------------------------------------|---------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------|
| T cell lines                             | Integration   | DNA digestion (AvrII/Xbal/SpeI or MseI) Linker ligation First PCR (LTR-linker) Nested PCR TOPO cloning and transformation Sanger sequencing | Trimming: custom Perl scripts Genome alignment: BLAT Integration site inclusion criteria: starting at junction with HIV LTR, mapping to the human genome reference sequence with >98 % identity Annotation databases: RefSeq (Assembly, GenScan, Unigene) | Lewinski et al. [51] (Sherrill-Mix et al. [42••]) |
| Proteome                                | Two-dimensional gel electrophoresis matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) | | Protein identification: ProFound, Prospector, and Mascot software | Berro et al. [95] |
| Bcl-2-modified CD4+ T cell model         | Integration   | DNA digestion (PstI) Dilution and circularization by ligation Inverse PCR amplification Sequencing | Sequence alignment using the UCSC Bioinformatics Human Genome database Integration site inclusion criteria: HIV LTR sequence | Shan et al. [54] Sherrill-Mix et al. [42••] |
| CD4+ T cell co-culture with H80 feeder model | Transcriptome | Total RNA extraction Spike-in addition (ERCC Exfold) mRNA-Seq library preparation (TruSeq) mRNA sequencing (Illumina HiSeq 2000) | Trimming: Cutadapt (Illumina adapter removal) Quality filtering: prinseq (low quality and PHRED score reads filtering) Genome and transcriptome alignment: Tophat Differential expression analysis: DESeq Enrichment tests: Fisher’s exact test Online visualization tool: LITCHI1 (GuavaH2) | Mohammadi et al. [32••] |
| Direct infection of resting CD4+ T cells | Integration   | DNA digestion (Tsp509I or MseI) Linker ligation First PCR (LTR-linker) Nested PCR with barcoded primers containing sequencing adapters 454 sequencing | Integration analysis done by web-based tool InSiPiD3 Trimming Genome alignment: BLAT, hg18 Integration site inclusion criteria: LTR sequence, mapping to the human genome reference sequence within the first 3 base pairs (bp) and a unique alignment with >98 % identity Annotation database: RefSeq Statistical analysis: one-tailed Student’s t test, one-way ANOVA, logistic regression | Pace et al. [52] Sherrill-Mix et al. [42••] |
| Integration                             | DNA digestion (MseI) Linker ligation First PCR (LTR-linker) Nested PCR with barcoded primers containing sequencing adapters Ion Torrent sequencing (Ion PGM 200 sequencing, Ion 316 chip) | Integration analysis done by web-based tool InSiPiD3 Trimming: hiReadsProcessor R package Genome alignment: BLAT, hg19 Integration site inclusion criteria: LTR and primer sequences, mapping to the human genome reference sequence within the | Sherrill-Mix et al. [42••] |
| HIV latency models | Analysis type | Experimental approach | Computational tools/approaches | Reference |
|-------------------|---------------|-----------------------|-------------------------------|-----------|
| Transcriptome     | RNA extraction | RNA amplification     | Raw data processing and filtering using Bioconductor (R), Benjamini and Hochberg p value correction with a 0.05 false discovery rate | Evans et al. [78] |
|                   | Hybridization to Illumina | Human-Ref8 (v3) BeadChip (microarray) | Statistical analysis: R | |
|                   | Chip scanning with Illumina | BeadStation 500GX scanner using Illumina BeadStudio (version 3) software | Pathway enrichment analysis: Ingenuity Pathway Analysis (IPA) software | |
| Patient-derived ex vivo model | Integration | DNA shearing (Covaris Adaptive Focused Acoustics) into 300-500-bp fragments | Trimming: custom Perl scripts | Maldarelli et al. [44•] |
|                   | End repair (Epigenentre End-it DNA End Repair) | dA addition (NEB dA-tailing kit) | Genome alignment: BLAT, hg19 | |
|                   | Linker ligation | First PCR (LTR-linker) | Integration site inclusion criteria for read 1: LTR primer sequence, 5 last bp of the LTR sequence followed with >20-bp DNA sequence with an average quality score >20, mapping to the human genome reference sequence within the first 3 bp and with >95 % identity | |
|                   | Nested PCR with N6-barcoded primers containing sequencing adapters | Illumina sequencing: 2×150 bp paired-end (MiSeq) or 2×105 bp paired-end (HiSeq) | Integration site inclusion criteria for read 2: alignment to the human genome reference sequence on the opposite strand compared to read 1 and within 1 kb | |
|                   | | | Integration sites are considered different if the breaking point differs from >3 bp | |
|                   | | | Gene ontology analysis: GREAT | |
|                   | | | Statistical analysis: Fisher’s exact test | |
| Integration        | Linear amplification using forward primer in HIV 3′ end (env or nef region) | | Trimming: Sequencher | Wagner et al. [45•] |
|                   | Second-strand synthesis using a random decamer primer tailed with HIV U5 sequence | Genomic alignment: Bowtie2 (and BLAT), hg19 | Genome alignment: Bowtie2 and BLAT, hg19 | |
|                   | End repair by trimming (NEB exonuclease I first followed by MyTaq fill-in) | Annotation databases: RefSeq genes, UCSC known genes | Annotation databases: RefSeq genes, UCSC known genes | |
|                   | Denaturation, annealing, and extension to generate a panhandle structure (LTR sequence double-stranded and loop single-stranded DNA as host DNA) | Gene ontology analysis: TopGO | Gene ontology analysis: TopGO | |
|                   | PCR amplification with one specific LTR primer (R region) | Statistical analysis: Fisher’s exact test, Holm-Bonferroni correction, Cochran-Armitage test | Statistical analysis: Fisher’s exact test, Holm-Bonferroni correction, Cochran-Armitage test | |
|                   | Nested PCR with inner LTR primer (R or U5 region) | | | |
|                   | Sequencing using downstream U5 primer | | | |

1. LITCHI latent infection of T cells by HIV (http://litchi.labtelenti.org/)
2. GuavaH genomic utility for association and viral analyses in HIV (http://www.guavah.org/) [100]
3. InSiPiD integration site pipeline and database (http://www.bushmanlab.org/tools)
amplicon sequenced twice or from two individual integration events occurring at the same chromosomal position [43, 44•, 45•]. Maldarelli et al. and Wagner et al. observed that the same integration site was identified multiple times in latently infected cells, suggesting that a single infected cell was clonally expanded over time [44•, 45•]. The location of the proviral insertion in these clonally expanded infected cells was enriched in genes involved in cell division cycle or cancer, supporting the notion that the site of viral integration may promote homeostatic proliferation. It is important to note that, despite this observation, cancer due to HIV insertional mutagenesis is not a major issue in HIV-infected individuals [36, 46]. Alternative hypotheses explaining the observed cell clonal expansion include (i) the infection of stem cells [20, 21, 47, 48] and (ii) the possible survival advantage of cells carrying defective viral genomes [31••, 46]. It would thus be interesting to know if the expanded cell clones are part of the inducible or defective viral reservoir. This would guide viral eradication strategies to account for those cells and explore ways to specifically inhibit their proliferation.

The link between the integration site and HIV latency is considered to be at the transcriptional level, resulting in silencing via epigenetic regulation of the chromatin environment or transcriptional interference [25, 49, 50]. Spatial features of the integration site associated with transcriptional latency have been shown to favor (i) heterochromatin (centromeric alphoid repeats) and intergenic regions [51, 52], (ii) flanking cellular genes that are highly expressed [51, 53], and (iii) the same orientation as cellular genes [54]. In contrast, Dahabieh et al. suggested that NF-kB activity and cell activation state correlate with viral gene expression efficiency rather than genomic integration features [55].

The role of integration site location on HIV transcriptional activity has been recently assessed in five primary cell models of HIV latency, identifying features specific for each model [42••]. Viral silencing was stronger if the host gene expression was high in the Jurkat latent model and in active CD4+ T cells, while the contrary was observed in a central memory CD4+ T cell model. The same orientation integration bias in the Bcl-2 latency model was confirmed but was not identified in the other latency models [54]. Integration in intergenic regions was favored in active or resting CD4+ cell models only. In contrast, integration in alphoid repeats was preferentially identified in the Jurkat latency model, confirming a previous study, and in resting and central memory cell models [51]. Finally, only the H4K12ac acetylation epigenetic mark correlated with latency in active, resting, and central memory CD4+ cell models but not in the Bcl-2 and Jurkat cell line models. This study highlighted characteristics specific for each model but failed to identify common features of integration site selection specific of HIV latency across all latency models, leaving open the debate about the contribution of integration site location to transcriptional silencing [42••]. Single-cell analysis may facilitate understanding of the link existing between integration site location and viral transcription.

Transcriptome and HIV Latency

Transcriptome analyses capture a snapshot of RNA molecules within the cell at a specific time. The mRNA molecules will be translated shaping the proteome content of the cell and therefore its functionality. Although the transcriptome only partially correlates with the proteome, it still provides a valuable approximation of the cell condition at a specific time [56–58]. The amount of specific mRNA species results from a balance between the production rate and decay rate. The former is determined by an interplay of regulatory processes acting at transcription initiation, elongation, and termination steps, and the latter is influenced by proteins binding to the 3′ untranslated region (3′ UTR) and the activity of regulatory RNAs such as microRNAs and noncoding RNAs [59–68]. External stimuli will affect this balance, tipping it towards one direction or another [69, 70]. An additional layer of complexity resides in alternative splicing, for both HIV and host cells [59, 71–73].

Transcriptional silencing of HIV has been considered as a major cause of latency [25, 49, 50]. The majority of studies investigating transcriptional silencing have focused on mechanisms acting on the viral LTR promoter, highlighting the role of the viral Tat protein, cellular proteins, histone post-translational modifications, and chromatin remodeling [25, 49, 50, 74–77]. However, only a few studies have focused on the transcriptome analysis of latently infected cells. Evans et al. developed a new primary model of HIV latency, which consists in co-culturing resting CD4+ T cells with myeloid dendritic cells (mDC) for 24 h, followed by CCR5-tropic HIV-GFP infection [78]. Latently infected cells were defined as nonproliferating CD4+ T cells not expressing viral-encoded GFP and were thus sorted by fluorescence-activated cell sorting (FACS) as SNARF-1high and GFP− cells after 5 days post-infection. This model provided evidence that CD4+ T cell direct contact with mDC, but not plasmacytoid DC (pDC), facilitates establishment of HIV latency. The study used microarrays to compare latently infected CD4+ T cells versus mock-infected CD4+ T cells co-cultured with mDC and identified only a limited number of genes, mostly interferon I-regulated genes (IFIT1, IFI27, and OAS1), as differentially expressed. These genes may represent latency biomarkers but may also originate from noninfected exposed cells.

Gene arrays are being replaced by high-throughput sequencing technologies, as these do not require prior knowledge about gene sequences and provide a higher accuracy. Current methods differ in the library preparation and in the targeted RNA species. For example, total RNA sequencing...
Because of the difficulty to isolate and obtain an uncon-
CD4+ T cells in order to identify specific latency biomarkers
analyzing purified populations of latently infected resting
script isoforms. Messenger RNA-Seq (mRNA-
Se) is based on poly(A) capture, thereby requiring less
sequencing depth, and will reflect more faithfully the
coding transcripts, although it will not account for
coding transcripts that are not poly-adenylated [80, 81].
Recent improvements in library preparation protocols
include determination of RNA strand specificity as well
as of splicing variants of the coding transcripts. The
analysis of these sequences requires computational tools
to align the transcripts to the genome and identify tran-
script isoforms.

The analysis by Evans et al. highlighted the importance of
analyzing purified populations of latently infected resting
CD4+ T cells in order to identify specific latency biomarkers
[78]. Because of the difficulty to isolate and obtain an uncon-
taminated population of latently infected cells, only a limited
number of studies investigated the cellular transcriptome of
HIV latency in primary models. Mohammadi et al. used a
primary CD4+ T cell model infected with an attenuated viral
construct. Successfully infected cells were isolated and puri-
fied by FACS and allowed to revert to a resting, hence latent
state, by co-culture with H80 feeder cells [32••]. They anal-
alyzed the transcriptome of the infected cells over time by
mRNA-Seq, thereby following establishment of latency. Cell-
ular activation or resting state was shown to be a major driver
of transcriptional differences between cells. Except for the
persistent detection of viral transcripts, only a very limited
number of host genes were found to be differentially expressed between noninfected and latently infected cells, suggesting that HIV had a very minor impact on the tran-
scriptome of the resting cell. Latently infected cells were also
exposed for 8 and 24 h to diverse stimuli to reactivate latency,
including SAHA (vorinostat), disulfiram, and IL-7. Although
some of these molecules were impacting viral transcription,
they failed to stimulate viral protein expression, underscoring
the possibility that post-transcriptional blocks would also
contribute to the latent phenotype. This study indicated that
HIV latency reflects transcriptional and post-transcriptional
blocks, including nuclear export and translation [26••, 32••, 82]. The multiplicity of mechanisms leading to HIV latency
was also illustrated recently by the comparison of several
latency-reactivating agents and their different efficiencies
across latency models [26••].

Proteome and HIV Latency

The genetic flow of information in the cell attains a key
principal level with the translation of messenger RNA into
functional protein. Each protein is modulated through
tissue-specific dynamic processes such as alternative splic-
ing, post-translational modifications, interactions with oth-
er molecules, and formation of proteomic complexes,
which delineate the multidimensional complex nature of the
proteome. A recently published blueprint of the human
proteome reported approximately $3 \times 10^6$ unique peptides
covering 84 % of the annotated coding genome [83]. An-
alyzing the proteins of a biological system gives the op-
portunity to understand and reveal the intricacies of many
cellular functional pathways, inaccessible through genomic
or transcriptomic studies.

During HIV infection, as in the case of any viral
infection, the proteome of the infected host cell consti-
tutes a key layer where a plethora of responses and
interactions with the viral components take place [84,
85]. HIV orchestrates various cellular processes by inter-
acting and manipulating the functional blocks on
the host cell in order to promote viral replication and
assure its survival [86]. On the host side, various studies
have identified changes in post-translational modific-
ations, localization, and amount of proteins upon infection
by HIV [87, 88]. In addition to taking advantage of the
host cellular proteome, HIV brings along an arsenal of
15 viral proteins that interfere with the host cell, estab-
lish interactions, and carry diverse post-translational
modifications in order to assure key steps of the virus
life cycle.

Recent technological advances and the advent of mass
spectrometry (MS)-based proteomics have made a strong
positive impact on virology and have helped uncover and
characterize many proteomic responses triggered by viral
infection [89, 90]. A standard MS experiment consists of a
succession of steps: sample protein fractionation into smaller
peptides, separation, ion detection, and relative or absolute
protein quantitation. The general pipeline can be adapted to
address more specific questions such as studying alterations in
the phosphoproteome [91]. Online databases and search algo-
rithms are used to map the obtained peptides to putative
proteins. The resulting proteomic MS data has additional
complexity since, often, more than one candidate protein is
associated to the measurements from a set of peptides. A
necessary step in MS data pre-processing is to filter out
proteins with few, uncertain peptide measurements. MS ex-
periments allow obtaining relative or absolute protein mea-
surements between two different conditions (e.g., HIV-
infected and mock-infected cells) which need to be
normalized.

Jager et al. used affinity purification coupled with MS (AP-
MS) to construct a map of HIV-host interactions at the prote-
ome level. The authors devised a scoring system coined MIST
which incorporates the reproducibility, abundance, and spec-
icity of a protein to filter out nonspecific interactions. They
reported on 497 high-confidence interactions, mainly enriched in transcription and regulation of viral protein post-translational modifications [92]. Another study employed isobaric tags for relative and absolute quantitation (iTRAQ) coupled with tandem MS to determine the host proteome response to HIV infection in a time-dependent manner [93]. Differentially expressed proteins were identified between HIV- and mock-infected samples at three different time points post-infection. Interestingly, the groups of differentially expressed proteins differed between early and late time points, capturing an early response enriched for cell proliferation, protein synthesis, DNA recombination, repair, and maintenance versus a late reaction linked to T cell activation [93]. Stable isotope labeling by amino acids in cell culture (SiLC) profiling of phosphopeptides during HIV entry in the host cell has revealed responses to HIV infection at the level of the host phosphoproteome, notably suggesting that HIV affects the phosphorylation of serine-rich host proteins to ease its replication and subsequent release [94•].

A series of host transcription factors, such as NF-kB, NFAT, or Sp1, bind to the HIV promoter, thereby modulating viral transcriptional activity in infected CD4+ T cells. Their nuclear availability varies between active and resting, latently infected cells [25, 95, 96]. Furthermore, reversible post-translational modifications of histones, such as deacetylation, have been found to play an important role in the establishment and maintenance of latency by modeling the neighboring chromatin organization at the viral LTR promoter [25, 27, 49, 50]. At the membrane level, 17 proteins involved in cell survival pathways or in the regulation of cellular adherence and transfer were found to be disrupted in latently infected cells [97]. The same study also showed that targeted treatment with inhibitors of several of these proteins, precisely XIAP and BTK, influenced the viability of latently infected cells [97]. Understanding the molecular pathways contributing to HIV latency at the proteome level may help in designing novel treatments to eliminate the quiescent virus.

Little is known about HIV-host interactions and the host proteome response during latency and reactivation. To date, no study has compared the whole proteomes of latent and activated HIV-infected cells. Glycoproteomic tandem MS has been employed to profile the disruption in glycoprotein secretion from latently HIV-infected T cells and to identify aberrantly secreted proteins in plasma from infected patients. Six glycoproteins, L-selectin, galectin, galectin-3-binding protein, CECR1, ICOS, and the phospholipid transfer protein, were found to be overly secreted by latently infected T cells and elevated in patient plasma [98]. Although the mechanisms through which these proteins contribute to HIV latency remain elusive, this study represents a starting point to explore how latency alters protein secretion of the host cell. Another recent study focused on characterizing histone post-translational modifications in SupT1 cell lines infected with HIV, UV-inactivated HIV, and mock-infected in order to find a link to the transcriptional behavior of the cell. Using nano-LC-MS/MS, a set of histone modifications was detected in HIV- versus mock-infected cells, providing insight on how the virus modulates chromatin accessibility to assure its transcription during infection [99]. This study illustrates the epigenetic mechanisms used to manipulate chromatin to ensure transcriptional silencing during latency. Improvements of measurement investigation techniques and joint analyses of all post-translational modifications should help in assembling a complete view of the whole cellular proteome, thereby informing on the identity and the role of specific modified proteins in the process of latency.

Conclusions

Unraveling the different aspects of latency will be a major step towards efficient HIV treatment and eradication. However, HIV latency and its reactivation have proven to be complex processes with many confounding factors. Genome-wide data provide a snapshot of the latently infected cell, at different molecular levels, i.e., integration site, transcriptome, and proteome. However, several aspects may influence the analysis: (i) The resting status of the cell limits the possibility of identifying unique markers of latency, (ii) the presence of a large number of infected cells carrying defective viral genome sequences obscures the features of the latent viral reservoir that can be reactivated with the goal of cure, and (iii) the analysis of high-throughput genome-wide data is particularly challenging due to the large amount of data as well as systematic technological and biological noise that may lead to high false-positive rates. Adequate bioinformatic tools are required to account for these effects in order to process and analyze the data. In-depth and dynamic genome-wide studies can provide essential contributions to the understanding of establishment of latency during resting condition, maintenance of latency, and the steps towards full reactivation.

Acknowledgments

This work was supported by the Swiss National Science Foundation (grant 31003A_146579; www.snf.ch). Julia di Iulio is a recipient of a fellowship from the Swiss National Science Foundation.

Compliance with Ethics Guidelines

Conflict of Interest

Angela Ciuffi, Pejman Mohammadi, Monica Golumbeau, Julia di Iulio, and Amalio Telenti declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Siliciano JD, Siliciano RF. The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS. 2006;1:121–8.
2. Durand CM, Blankson RN, Siliciano RF. Developing strategies for HIV-1 eradication. Trends Immunol. 2012;33:554–62. Excellent review and overview of the obstacle of the HIV reservoir and the strategies to eliminate it.
3. Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345:169–74.
4. Barton KM, Burch BD, Soriano-Sarahia N, Margolis DM. Prospects for treatment of latent HIV. Clin Pharmacol Ther. 2013;93:46–56.
5. Abou-El-Enein M, Bauer G, Reinke P, Renner M, Schneider CK. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med. 2014;20(11):632–42.
6. Kent SJ, Reece JC, Petracik J, Martyushev A, Kramski M, De Rose R, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis. 2013;13:614–21.
7. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7:798–812.
8. Whitney JB, Hill AL, Sanisette S, Penaloza-MacMaster P, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512:74–7. This study shows that upon viral infection the viral reservoir is established very early (in less than three days) in an animal model. This study also shows that HIV is detectable in lymph nodes but not in blood of some animals, suggesting that lymph nodes may be an early and important reservoir.
9. Zaikos TD, Collins KL. Long-lived reservoirs of HIV-1. Trends Microbiol. 2014;22:173–5.
10. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37:377–88.
11. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology. 2009;6:51.
12. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111:2307–12.
13. Costiniuk CT, Jenabian MA. Cell-to-cell transfer of HIV infection: implications for HIV viral persistence. J Gen Virol. 2014;95:2346–55.
14. Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9:552–8.
15. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnolo RA, Snyder OD, et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 2014;10:e1003872.
16. Soriano-Sarahia N, Bateson RE, Dahl NP, Crooks AM, Kumuc JD, Margolis DM, et al. The quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells. J Virol. 2014;88:14070–7.
17. Kumar A, Abbas K, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses. 2014;6:1837–60.
35. Desfarges S, Ciuffi A: Viral integration and consequences on host gene expression. In: Viruses: essential agents of life. Edited by Witzany G; Springer Science+Business Media; 2012.
36. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther. 2008;8:419–29.
37. Desfarges S, Ciuffi A. Retroviral integration site selection. Viruses. 2010;2:111–30.
38. Ciuffi A, Talenti A. State of genomics and epigenomics research in the perspective of HIV cure. Curr Opin HIV AIDS. 2013;8:176–81.
39. Ciuffi A, Barr SD. Identification of HIV integration sites in infected host genomic DNA. Methods. 2011;53:39–46.
40. Ciuffi A, Ronen K, Brady T, Malani N, Wang G, Berry CC, et al. Methods for integration site distribution analyses in animal cell genomes. Methods. 2009;47:261–8.
41. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Ocwieja KE, et al. HIV latency and integration site placement in the perspective of HIV cure. Curr Opin HIV AIDS. 2013;10:11.
42. • Sherrell-Mix S, Lewinski MK, Famiglietti M, Bosque A, Malani N, Ocwieja KE, et al. HIV latency and integration site placement in five cell-based models. Retrovirology. 2013;10:90. A comparative study of latency models to identify genomic features of integration site locations specific of HIV latency.
43. Fiouzi S, Lopez Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-I-infected cells based on provirus integration sites. Genome Med. 2014;6:46.
44. • Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014;345:179–83. This study identified clonal expansion of some infected cells in HIV+ individuals.
45. • Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345:570–3. This study identified clonal expansion of some infected cells in HIV+ individuals.
46. Margolis D, Bushman F. HIV/AIDS. Persistence by proliferation? Science. 2014;345:143–4.
47. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med. 2014;20:139–42.
48. Powers JM, Trobridge GD. Identification of hematopoietic stem cell engraftment genes in gene therapy studies. J Stem Cell Res Ther. 2013;2013:
49. Van Lint C, Bouchat S, Marcello A. HIV-1 transcription and latency: an update. Retrovirology. 2013;10:67.
50. Mbonye U, Kam J. Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology. 2014;454–455:328–39.
51. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol. 2005;79:6601–9.
52. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, et al. Directly infected resting CD4+ T cells can produce HIV Gag without spreading infection in a model of HIV latency. Proc Natl Acad Sci U S A. 2012;109:7109–13.
53. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol. 2004;78:6122–33.
54. Shan L, Yang HC, Rabi SA, Bravo HC, Shroff NS, Iritarry RA, et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011;85:5384–93.
55. Dahabieh MS, Ooms M, Brumme C, Taylor J, Harrigan PR, Simon V, et al. Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFkappaB. Retrovirology. 2014;11:17.
56. Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hapogian R, Munganee IN, et al. Comparative analysis of proteome and transcriptome variation in mouse. Proc Natl Acad Sci U S A. 2011;108:10003–8.
57. Low TY, van Heesch S, van den Toorn H, Giansanti P, Cristobal A, Toonen P, et al. Quantitative and qualitative proteome characteristics extracted from in-depth integrated genomics and proteomics analysis. Cell Rep. 2013;5:1469–78.
58. Fu X, Fu N, Guo S, Yan Z, Xu Y, Hu H, et al. Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics. 2009;10:161.
59. Bentley DL. Coupling mRNA processing with transcription in time and space. Nat Rev Genet. 2014;15:163–75.
60. Groen JN, Caprao D, Morris KV. The emerging role of pseudogene expressed non-coding RNAs in cell functions. Int J Biochem Cell Biol. 2014;54:330–5.
61. Groen JN, Morris KV. Chromatin, non-coding RNAs, and the expression of HIV. Virus. 2013;5:163–45.
62. Swaminathan S, Kelleher AD. MicroRNA modulation of key targets associated with T cell exhaustion in HIV infection. Curr Opin HIV AIDS. 2014;9:464–71.
63. Chiang K, Rice AP. MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses. 2012;4:390–409.
64. Fowler L, Saksena NK. Micro-RNA: new players in HIV-pathogenesis, diagnosis, prognosis and antiviral therapy. AIDS Rev. 2013;15:3–14.
65. Swaminathan G, Navas-Martín S, Martín-García J. MicroRNAs and HIV-1 infection: antiviral activities and beyond. J Mol Biol. 2014;426:1178–97.
66. Cox JE, Sullivan CS. Balance and stealth: the role of noncoding RNAs in the regulation of virus gene expression. Ann Rev Virol. 2014;1:89–109.
67. Saayman S, Ackley A, Turner AM, Famiglietti M, Bosque A, Clemson M, et al. An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription. Mol Ther. 2014;22:1164–75.
68. Chang H, Lim J, Ha M, Kim VN. TAIL-seq: genome-wide determination of poly(A) tail length and 3’ end modifications. Mol Cell. 2014;53:1044–52.
69. Weake VM, Workman JL. Inducible gene expression: diverse regulatory mechanisms. Nat Rev Genet. 2010;11:426–37.
70. Voss TC, Hager GL. Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet. 2014;15:69–81.
71. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, Schaller T, et al. HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog. 2011;7:e1001313.
72. Imbeault M, Giguerre K, Onelett P, Tremblay MJ. exon level transcriptomic profiling of HIV-1-infected CD4(+ ) T cells reveals virus-induced genes and host environment favorable for viral replication. PLoS Pathog. 2012;8:e1002861.
73. Wan Y, Qu K, Zhang QC, Flynn RA, Manor O, Ouyang Z, et al. Landscape and variation of RNA secondary structure across the human transcriptome. Nature. 2014;505:706–9.
74. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 2013;10:11.
75. Lusie M, Giacca M. Regulation of HIV-1 latency by chromatin structure and nuclear architecture. J Mol Biol. 2014. doi:10.1016/j.jmb.2014.07.022.
76. Park J, Lim CH, Ham S, Kim SS, Choi BS, Roh TY. Genome-wide analysis of histone modifications in latently HIV-1 infected T cells. AIDS. 2014;28:1719–28.

77. Jadlowsky JK, Wong JY, Graham AC, Dobrowolski C, Devor RL, Adams MD, et al. Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat. Mol Cell Biol. 2014;34:1911–28.

78. Evans VA, Kumar N, Filali A, Procopio FA, Yegorov O, Goulet JP, et al. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells. PLoS Pathog. 2013;9:e1003799.

79. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316:1484–8.

80. Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL. Genomewide characterization of non-polyadenylated RNAs. Genome Biol. 2011;12:R16.

81. Marzluff WF, Wagner EJ, Duronio RJ. Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet. 2008;9:843–54.

82. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2006;2:e68.

83. Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.

84. Zhang L, Zhang X, Ma Q, Zhou H. Host proteome research in HIV infection. Genom, Proteome Bioinforma. 2010;8:1–9.

85. Zhu J, Davoli T, Perriera JM, Chin CR, Gaiha GD, John SP, et al. Comprehensive identification of host modulators of HIV-1 replication using multiple orthogonal RNAi reagents. Cell Rep. 2014;9:752–66.

86. Malim MH, Bieniasz PD. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med. 2012;2:a006940.

87. Deboer J, Jagadish T, Haverland NA, Madson CJ, Ciborowski P, Belsham M. Alterations in the nuclear proteome of HIV-1 infected T-cells. Virology. 2014;468-470:409–20.

88. Haverland NA, Fox HS, Ciborowski P. Quantitative proteomics by SWATH-MS reveals altered expression of nucleic acid binding and regulatory proteins in HIV-1-infected macrophages. J Proteome Res. 2014;13:2109–19.

89. Greco TM, Diner BA, Cristea IM. The impact of mass spectrometry-based proteomics on fundamental discoveries in virology. Ann Rev Virol. 2014;1:581–604.

90. Weeves MP, Tomasec P, Hutlin EL, Fielding CA, Nusinow D, Stanton RJ, et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell. 2014;157:1460–72.

91. Altelaa AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet. 2013;14:35–48.

92. Jager S, Cimermanic P, Guibahue N, Johnson JR, McGovern KE, Clarke SC, et al. Global landscape of HIV-human protein complexes. Nature. 2012;481:365–70.

93. Navare AT, Sova P, Purdy DE, Weiss JM, Wolf-Yadlin A, Korth MJ, et al. Quantitative proteomic analysis of HIV-1 infected CD4+ T cells reveals an early host response in important biological pathways: protein synthesis, cell proliferation, and T-cell activation. Virology. 2012;429:37–46.

94. Wojcieszowsk JA, Didigu CA, Lee JY, Parrish NF, Sinha R, Hahn BH, et al. Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe. 2013;13:613–23. This paper is the first phosphoproteomic study in a natural infection design, i.e. X4-tropic HIV on primary CD4+ T cells.

95. Pan X, Baldauf HM, Keppler OT, Fackler OT. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes. Cell Res. 2013;23:876–85.

96. Zack JA, Kim SG, Vatakis DN. HIV restriction in quiescent CD4+ T cells. Retrovirology. 2013;10:37.

97. Berro R, de la Fuente C, Klase Z, Kehn K, Parvin L, Pumfery A, et al. Identifying the membrane proteome of HIV-1 latently infected cells. J Biol Chem. 2007;282:8207–18.

98. Yang W, Zhou J-Y, Chen L, Sun S, Aiyetan P, et al. Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV+ plasma. Clin Proteome. 2014;13:926–36.

99. Britton LM, Sova P, Belisle S, Liu S, Chan EY, Katze MG, et al. A proteomic glimpse into the initial global epigenetic changes during HIV infection. Proteomics. 2014;14:2226–30.

100. Bartha I, McLaren PJ, Ciuffi A, Fellay J, Telenti A. GuavaH: a compendium of host genomic data in HIV biology and disease. Retrovirology. 2014;11:6.